EP0541694A1 - Method for treating immune system dysfunctions - Google Patents

Method for treating immune system dysfunctions

Info

Publication number
EP0541694A1
EP0541694A1 EP91915040A EP91915040A EP0541694A1 EP 0541694 A1 EP0541694 A1 EP 0541694A1 EP 91915040 A EP91915040 A EP 91915040A EP 91915040 A EP91915040 A EP 91915040A EP 0541694 A1 EP0541694 A1 EP 0541694A1
Authority
EP
European Patent Office
Prior art keywords
immune system
patient
lys
dynorphin
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91915040A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0541694A4 (enExample
Inventor
Nancy M. Lee
Horace H. Loh
S. Ramakrishnan
Sabita Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0541694A1 publication Critical patent/EP0541694A1/en
Publication of EP0541694A4 publication Critical patent/EP0541694A4/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention generally relates to a method of treating immune system dysfunctions with an opioid peptide, and more particularly to the use of dynorphin in either stimulating the immune system of a patient whose immune system is impaired or by suppressing the immune system of a patient whose immune system is hyperactivated.
  • virus infections such as HTLV lead to the specific elimination of CD4 positive T helper cell population.
  • immuno suppressed individuals show increased incidents of EBV associated ly phomas and other diseases associated with secondary infection.
  • bone marrow transplant recipients whose immune systems have been affected by chemo-radiation therapy, incur a risk of developing lymphomas.
  • problems associated with the immune system have also been noticed in drug addicts, who comprise a subpopulation vulnerable to infection by the AIDS virus. These all appear to involve aberrant immune system suppression.
  • aberrant immune system activation examples include the autoimmune diseases, such as rheumatoid arthritis, myasthenia gravis, and the like.
  • Present drug therapies for aberrant immune system activation such the widely used immuno suppressive compound Cyclosporin A, have restriction on long term use due to side effects.
  • Investigators have recently begun attempts to link immuno regulation to neural opioid systems. It has become increasingly clear there are a number of opioid effects on cells of the immune system, but the mechanisms remain obscure. The authors of a recent review have concluded that the significance of opioids in immune system function remain a matter for speculation. Sibinga and Goldstein, Ann. Rev. Inanunol . , 6, pp. 219-249 (1988) .
  • the endogenous opioids exist in multiple forms in the central nervous system and include the dynorphins, a series of peptides derived from the precursor prodynorphin (proenkephalin B) . Unlike either the enkephalins or the endorphins, many of the dynorphins interact with high affinity with all three major opioid receptor types ( ⁇ , ⁇ , and c) . The dynorphins are also nearly unique among endogenous opioids in that they are not analgesic in the brain, although they may be in the spinal cord.
  • AA is isoleucine, leucine, or lysine
  • AA 9 is arginine or proline
  • AA is proline
  • a carbonyl carbon at the AA 10 terminus is amidated.
  • dynorphin (1-10) amide analogs do not have significant analgesic activity (unless given in huge doses where they tend to produce convulsions) , but they differ from dynorphin (1- 13) by neither potentiating nor antagonizing morphine in naive animals. In tolerant animals, on the other hand, the dynorphin (1-10) amide analogs appear to be a more potent and selective analog than dynorphin (1-13) .
  • dynorphin in treating high blood pressure modifies the autonomic nervous system so as to amplify and maintain the intensity of endogenous opioid peptides.
  • a mode of action may be by increasing the sensitivity of visceral afferent receptors.
  • U.S. Patent 4,684,624, issued August 4, 1987, inventors Hosobuchi et al. describe the use of dynorphin-related peptides, in the acid or amidated form, to treat patients suffering from cerebral ischemia.
  • the administration of these opioid peptides to patients suffering from acute focal cerebral ischemia has been found useful in prolonging survival, and appears useful in partially reversing neurologic deficits resulting from cerebral ischemia.
  • Fig. 1 graphically illustrates the suppression, or inhibition, of macrophage colony forming units by morphine
  • Fig. 2 graphically illustrates the reversal of morphine induced inhibition of macrophage colony forming units by dynorphin (1-10) amide;
  • Fig. 3 graphically illustrates the reversal of morphine induced inhibition of thymocyte proliferation by dynorphin (1-10) amide; and Fig. 4 graphically illustrates the dose dependent effect of dynorphin on macrophage colony forming units.
  • the present invention provides a method for stimulating or suppressing the immune system of a patient by administrating different amounts of a dynorphin in the acid form or amide form.
  • the dynorphin administered is an opioid peptide and when in acid form is administered in less than about 200 ⁇ g/kg body weight per dose to a patient whose immune system is impaired, so that the immune system is stimulated.
  • the dose in acid form is greater than about 500 ⁇ g/kg body weight to a patient whose immune system is stimulated, such as by a autoimmune disease, then the immune system is suppressed.
  • a particularly preferred aspect of the inventive method is to stimulate the immune system of a patient whose immune system is impaired, such as by chronic use of a narcotic analgesic or during chemo- radiation therapy.
  • dynorphin and its analogs when in the acid form, have a biphasic activity.
  • the acid form of dynorphin or its analogs stimulates an immune system that is impaired.
  • the effect is just the opposite and suppresses the immune system.
  • Suitable compounds for practicing the invention will generally be referred to by the designation "dynorphin,” and have as the first seven amino acids:
  • the naturally occurring dynorphin has seventeen amino acids, where eight through seventeen are as follows:
  • Dynorphin analogs that are also suitable in practicing the invention include opioid peptides having at least ten amino acids and optionally with one or more amino acid substitutions (with respect to naturally occurring dynorphin) in the amino acid positions eight through seventeen.
  • suitable compounds for practicing the inventive method also include within the "dynorphin" designation those having the following structure:
  • AA 8 is TYR, ILE, LEU, or LYS
  • AA 9 is ARG or PRO
  • AA 10 is PRO or LYS
  • AA 11 is LYS, LYS-LEU, or LYS-LEU-LYS
  • w is 0 or 1.
  • Either the acid or the amidated form of dynorphins can be used to practice the immune system stimulating aspect of the invention. Unlike the acid form, the amidated form of dynorphin does not appear to have the biphasic effect. Thus, in the particularly preferred method for stimulating the immune system the amidated form of dynorphin is preferred.
  • dynorphin (1-10) amide or (1- 13) amide where the AA is ILE, AA is ARG, and AA 10 is PRO, and when present, AA 1 is LYS, AA 12 is LEU, and AA 13 is LYS.
  • AA 1 is LYS
  • AA 12 is LEU
  • AA 13 is LYS.
  • narcotic abuse affects all the major components of the immune system (T-cells, B-cells, and accessory cells) since macrophages play a crucial role in the presentation of antigens to T-cells and are pivotal in the phagocytosis and elimination of infectious agents.
  • narcotic analgesics such as morphine, heroin, and others such as those narcotic analgesics clinically used, predisposes the users to a variety of pathological conditions due to immune system suppression.
  • mice were implanted with morphine (75 mg) pellets (72 hour pellets) and at different time points, animals were sacrificed. The functional status of the thymocytes and spleen cells were investigated. Mitogenic stimulation assays were used to determine the proliferative capacity (since immunocompetent cells proliferate after activation) .
  • M-CSF which is a growth factor involved in the production and functional maturation of macrophages
  • dynorphin by itself, is not inhibitory to immune cell proliferation, but antagonizes the inhibitory properties of morphine.
  • the use of dynorphin improves the macrophage colony formation which had been suppressed by morphine treatment. This is shown by the data of Fig. 2.
  • addition of dynorphin to thymocytes prevented the morphine induced suppression of proliferation, as seen by the data of Fig. 3.
  • Fig. 4 shows that similar effects can be observed in morphine tolerant animals that are injected with either 2 mg or 4 mg/kg body weight of dynorphin.
  • animals were implanted with either a 75 mg morphine pellet or a placebo pellet.
  • Each group then received 12 hourly injection of either 2 or 4 mg/kg body weight of dynorphin.
  • Fig. 4 there was a 60% reduction in the bone marrow colony forming units in the morphine tolerant animals injected with saline when compared with the placebo animals injected with saline.
  • Suitable dynorphin compounds for practice of the present invention can be by methods and apparatus known to the art for peptide synthesis.
  • Doses can be administered by intravenous, subcutaneous, or intramuscular injection (I.V., S.C. or I.M) or orally.
  • I.V. intravenous, subcutaneous, or intramuscular injection
  • a preferred range for stimulating the immune system of patient whose immune system is impaired is the administration of between about 10 ⁇ g/kg to about 200 ⁇ g/kg of body weight, most preferably about 50 ⁇ g/kg body weight. Administration can precede the events causing immune system impairment. For example, several hours before chemo-radiation a dose of dynorphin can be administered, preferably followed subsequent to the irradiation by several spaced apart subsequent doses.
  • mice are believed to be about 20 to 50 times more sensitive to the dynorphin concentrations than mice (although mice are a very good predictive model, except for this difference in dosage sensitivity) .
  • Example 1 more fully describes the protocol from which the data of Fig. 1 was taken.
  • Example 2 describes the protocol from which Fig. 2 taken, and similarly Example 3 for Fig. 3.
  • Example 4 describes dynorphin reversal studies.
  • ICR mice from Harlan were used in most studies to see the effect of chronic morphine pellet implanta- tion on stem cell proliferation. Similar studies were done on Balb C mice from Jackson Labs.
  • mice were implanted with two pellets: (1) a
  • the femurs from both treated and untreated animals were removed aseptically.
  • the bone marrow was flushed through the cut ends by injecting with Iscoves Modified Duelbco Medium using a 30 gauge needle.
  • One million nucleated cells were resuspended in 0.3% agarose prepared in IMDM containing 30% FCS and plated in a 35 mm petri dish with grids. Colony formation was assessed by treating the bone marrow cells with two different lineage specific growth factors, i.e. recombinant M-CSF (2.5 ng/ml) or mouse GM-CSF (1 ng/ml) for a period of 5 days. The colonies formed were scored using an inverted phase contrast microscope.
  • ICR mice from Harlan were used in most studies to see the effect of chronic morphine pellet implanta ⁇ tion on stem cell proliferation. Similar studies were done on Balb C mice from Jackson Labs. In these studies bone marrow was obtained from untreated naive animals. The bone marrow was assayed from macrophage colonies (CFU-M) and granulocyte- macrophage colonies (CFU-GM) over a range of dynorphin concentration with 100 ⁇ M being the highest concentration and 1 nm being the lowest.
  • CFU-M macrophage colonies
  • CFU-GM granulocyte- macrophage colonies
  • the femurs from both treated and untreated animals were removed aseptically.
  • the bone marrow was flushed through the cut ends by injecting with Iscoves Modified Duelbco Medium using a 30 gauge needle.
  • One million nucleated cells were resuspended in 0.3% agarose prepared in IMDM containing 30% FCS and plated in a 35 mm petri dish with grids. Colony formation was assessed by treating the bone marrow cells with two different lineage specific growth factors, i.e. recombinant M-CSF (2.5 ng/ml) or mouse GM-CSF (1 ng/ml) for a period of 5 days. The colonies formed were scored using an inverted phase contrast microscope.
  • ICR mice from Harlan were used in most studies to see the effect of chronic morphine pellet implanta ⁇ tion on stem cell proliferation. Similar studies were done on Balb C mice from Jackson Labs.
  • Thymus was removed aseptically from treated and untreated animals and passed through a nylon mesh to dissociate the cells. The cells were counted using the trypan blue dye exclusion method. The cells were then plated at a cell density of 1 x 10 cells per well in a 96 well plate. Thymocyte proliferation was determined by culturing the cell in the presence of 1 ⁇ g/ml IL-1.
  • ICR mice from Harlan were used in most studies to see the effect of chronic morphine pellet implanta ⁇ tion on stem cell proliferation. Similar studies were done on Balb C mice from Jackson Labs. Mice were implanted with two pellets: (1) a
  • mice were implanted with either a single morphine pellet (group 1) or a placebo pellet (group 2) . Each group was subdivided into 2 subgroups: A and B. Animals in group A received 4 mg/kg body weight Dynorphin (1-13) injections every 12 hours. The animals in group B received saline injections. The animals were maintained on this 12 hourly dynorphin injection regime for 72 hours after pellet implantation and then sacrificed.
  • the femurs from both treated and untreated animals were removed aseptically.
  • the bone marrow was flushed through the cut ends by injecting with Iscoves Modified Duelbco Medium using a 30 gauge needle.
  • One million nucleated cells were resuspended in 0.3% agarose prepared in IMDM containing 30% FCS and plated in a 35 mm petri dish with grids. Colony formation was assessed by treating the bone marrow cells with two different lineage specific growth factors, i.e. recombinant M-CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
EP91915040A 1990-08-03 1991-08-02 Method for treating immune system dysfunctions Withdrawn EP0541694A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56239390A 1990-08-03 1990-08-03
US562393 1990-08-03

Publications (2)

Publication Number Publication Date
EP0541694A1 true EP0541694A1 (en) 1993-05-19
EP0541694A4 EP0541694A4 (enExample) 1994-03-09

Family

ID=24246112

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91915040A Withdrawn EP0541694A1 (en) 1990-08-03 1991-08-02 Method for treating immune system dysfunctions

Country Status (5)

Country Link
EP (1) EP0541694A1 (enExample)
JP (1) JPH06501930A (enExample)
AU (1) AU660420B2 (enExample)
CA (1) CA2088679A1 (enExample)
WO (1) WO1992002547A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817628A (en) * 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
US20190241660A1 (en) * 2017-12-05 2019-08-08 Intendet Services, Llc Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757049A (en) * 1981-10-05 1988-07-12 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system of patients with aids
US4801614A (en) * 1981-10-05 1989-01-31 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells
US4537878A (en) * 1981-10-05 1985-08-27 Tni Pharmaceuticals, Inc. Process for using endogenous enkephalins and endorphins to stimulate the immune system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9202547A1 *

Also Published As

Publication number Publication date
AU660420B2 (en) 1995-06-29
CA2088679A1 (en) 1992-02-04
JPH06501930A (ja) 1994-03-03
AU8433391A (en) 1992-03-02
WO1992002547A1 (en) 1992-02-20
EP0541694A4 (enExample) 1994-03-09

Similar Documents

Publication Publication Date Title
Del Gobbo et al. Pinealectomy inhibits interleukin-2 production and natural killer activity in mice
Shavit et al. Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity
De Sarro et al. Behavioural and ECoG spectrum changes induced by intracerebral infusion of interferons and interleukin 2 in rats are antagonized by naloxone
Weber et al. The periaqueductal gray matter mediates opiate-induced immunosuppression
CA2137916A1 (en) Des-tyr dynorphin analogues
Fischer et al. β-Endorphin modulates immune functions: A review
Weber et al. Opiate receptor mediated regulation of the immune response in vivo
Dafny et al. Immune response products alter CNS acitivity: Interferon modulates central opioid function
CA2199730A1 (en) Protection of hemopoietic cells during chemotherapy or radiotherapy
Mastino et al. Combination therapy with thymosin α1 potentiates the anti‐tumor activity of interleukin‐2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice
Takahashi et al. A tumor necrosis factor (TNF) receptor fragment attenuates TNF‐α‐and muramyl dipeptide‐induced sleep and fever in rabbits
Woody et al. Prolactin exerts hematopoietic growth-promoting effects in vivo and partially counteracts myelosuppression by azidothymidine
Maestroni MLT and the immune-hematopoietic system
Saphier et al. α-Interferon inhibits adrenocortical secretion via μ1-opioid receptors in the rat
US5534495A (en) Treatment of non-HIV neuropathic pain syndromes
AU660420B2 (en) Method for treating immune system dysfunctions
Fride et al. Immunoenhancing effects of alprazolam in mice
US4801614A (en) Process for using endogenous enkephalins and endorphins to inhibit growth of tumerous cells
Parker et al. Inhibitors of haemopoiesis and their potential clinical relevance
Garaci et al. A synthetic analog of prostaglandin E2 is able to induce in vivo theta antigen on spleen cells of adult thymectomized mice
Greenberg et al. Neurohormonal modulation of natural resistance to a murine lymphoma
EP0076676B1 (en) Process for using endorphins as antitumour agents
Wybran Enkephalins as molecules of lymphocyte activation and modifiers of the biological response
Roy et al. Dynorphin blocks opioid inhibition of macrophage-colony stimulating factor-induced proliferation of bone marrow cells
US5807827A (en) Des-Tyr dynorphin analogues

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940120

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950814

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19951228